YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology Ecosystem [Yahoo! Finance]
YD Bio Limited - Ordinary Shares (YDES)
Company Research
Source: Yahoo! Finance
company advancing DNA methylation-based cancer detection technology and ophthalmologic innovations, today highlighted the strategic roadmap shared by CEO Dr. Ethan Shen in a recent interview with PharmaBoardroom, a UK-based platform providing insights to the global healthcare and life sciences community. Moving beyond the traditional single-asset biotech model, YD Bio Ltd is building a comprehensive ecosystem that synchronizes diagnostic intelligence with advanced therapeutic execution. In the interview, Dr. Shen addressed the Company's approach to the biotech sector, emphasizing integration of capabilities and describing YD Bio Ltd as an “operating system” for healthcare innovation under continuous construction. By integrating cancer detection technologies with late-stage dendritic cell immunotherapy programs, the Company aims to create a cohesive cycle of data-informed therapy and disciplined clinical translation. “Healthcare rarely fails because of a lack of effort. It fails beca
Show less
Read more
Impact Snapshot
Event Time:
YDES
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
YDES alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
YDES alerts
High impacting YD Bio Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
YDES
News
- YD Bio Limited CEO Dr. Ethan Shen Details Strategic Roadmap for Integrated Oncology EcosystemGlobeNewswire
- YD Bio (YDES) was upgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=YDES&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from "sell" to "hold".MarketBeat
- YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory PlatformGlobeNewswire
- YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy [Yahoo! Finance]Yahoo! Finance
- YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell TherapyGlobeNewswire
YDES
Sec Filings
- 3/18/26 - Form 3
- 2/27/26 - Form 424B3
- 2/26/26 - Form 6-K
- YDES's page on the SEC website